The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.
Novo Nordisk is quietly coming out of the storm despite the prevailing pessimism, especially among retail investors. Click ...
13h
Layoffs are piling up, raising worker anxiety. Here are some companies that have cut jobs recently
Federal employees have encountered additional doses of uncertainty, impacting worker sentiment around the job market overall.
Apple became the first $1 trillion company on U.S. public markets in 2018. Six of the eight companies to follow in Apple’s ...
Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a ...
Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without ...
With one in eight adults taking drugs like Ozempic and Mounjaro, emerging evidence shows that the medication has potential to ...
Novartis raised its peak sales guidance for two of its biggest drugs--Kisqali for breast cancer and Scemblix for leukemia. It now forecasts Kisqali sales to top $10 billion at their peak, up from $8 ...
Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader at the nexus of serialization ...
Eli Lilly's tirzepatide acts on two hormonal pathways, so it's called a dual GIP/GLP-1 receptor agonist, and it entered the market as Mounjaro for Type 2 diabetes and as Zepbound for weight management ...
On November 14, Berenberg lowered its price target on Novo Nordisk A/S (NYSE:NVO) to DKK 400 from DKK 425 while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback